These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37682707)

  • 1. Methylation of KRAS by SETD7 promotes KRAS degradation in non-small cell lung cancer.
    Chiang CY; Fan S; Zheng H; Guo W; Zheng Z; Sun Y; Zhong C; Zeng J; Li S; Zhang M; Xiao T; Zheng D
    Cell Rep; 2023 Sep; 42(9):113003. PubMed ID: 37682707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SETD7 promotes metastasis of triple-negative breast cancer by YY1 lysine methylation.
    Gao L; Zhang J; Long Q; Yang Y; Li Y; Li G; Pu P; Tong S; He Y; Li Q; Chen Y; Liu Y; Kong X
    Biochim Biophys Acta Mol Basis Dis; 2023 Oct; 1869(7):166780. PubMed ID: 37286143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SETD7 Promotes Cell Proliferation and Migration via Methylation-mediated TAF7 in Clear Cell Renal Cell Carcinoma.
    Zhang J; Duan B; Li F; Jing X; Li R; Cai S; Cao L; Jiang Q; Zhou J; Zhou J; Qin Y; Wang X; Tong D; Huang C
    Int J Biol Sci; 2024; 20(8):3008-3027. PubMed ID: 38904013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysine N-methyltransferase SETD7 promotes bladder cancer progression and immune escape via STAT3/PD-L1 cascade.
    Lv J; Wu Q; Li K; Bai K; Yu H; Zhuang J; Sun H; Yang H; Yang X; Lu Q
    Int J Biol Sci; 2023; 19(12):3744-3761. PubMed ID: 37564199
    [No Abstract]   [Full Text] [Related]  

  • 5. Oncogenic KRAS effector USP13 promotes metastasis in non-small cell lung cancer through deubiquitinating β-catenin.
    Guo Y; Tian J; Guo Y; Wang C; Chen C; Cai S; Yu W; Sun B; Yan J; Li Z; Fan J; Qi Q; Zhang D; Jin W; Hua Z; Chen G
    Cell Rep; 2023 Dec; 42(12):113511. PubMed ID: 38043062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Research Progress of Role and Mechanism of SETD7 in Tumor Occurrence 
and Progression].
    Cao L; Wang M; Xu K
    Zhongguo Fei Ai Za Zhi; 2023 Jan; 26(1):38-45. PubMed ID: 36792079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of SETD7 promotes migration and invasion of lung cancer cells via JAK2/STAT3 pathway.
    Cao L; Ren Y; Guo X; Wang L; Zhang Q; Li X; Wu X; Meng Z; Xu K
    Int J Mol Med; 2020 May; 45(5):1616-1626. PubMed ID: 32323737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1.
    Wang Z; Petricca J; Liu M; Zhang S; Chen S; Li M; Besschetnova A; Patalano S; Venkataramani K; Siegfried KR; Macoska JA; Han D; Gao S; Vedadi M; Arrowsmith CH; He HH; Cai C
    Proc Natl Acad Sci U S A; 2023 Aug; 120(33):e2220472120. PubMed ID: 37549269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
    Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
    Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isoform-Specific Lysine Methylation of RORα2 by SETD7 Is Required for Association of the TIP60 Coactivator Complex in Prostate Cancer Progression.
    Song H; Chu JW; Park SC; Im H; Park IG; Kim H; Lee JM
    Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32120841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hexachlorophene, a selective SHP2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling pathways.
    Fu NJ; Xi RY; Shi XK; Li RZ; Zhang ZH; Li LY; Zhang GL; Wang F
    Toxicol Appl Pharmacol; 2022 Apr; 441():115988. PubMed ID: 35307375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells.
    Jiang L; Xu W; Chen Y; Zhang Y
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3231-3238. PubMed ID: 31373232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired AKT signaling and lung tumorigenesis by PIERCE1 ablation in KRAS-mutant non-small cell lung cancer.
    Roh JI; Lee J; Sung YH; Oh J; Hyeon DY; Kim Y; Lee S; Devkota S; Kim HJ; Park B; Nam T; Song Y; Kim Y; Hwang D; Lee HW
    Oncogene; 2020 Sep; 39(36):5876-5887. PubMed ID: 32728173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crosstalk between lysine methylation and phosphorylation of ATG16L1 dictates the apoptosis of hypoxia/reoxygenation-induced cardiomyocytes.
    Song H; Feng X; Zhang M; Jin X; Xu X; Wang L; Ding X; Luo Y; Lin F; Wu Q; Liang G; Yu T; Liu Q; Zhang Z
    Autophagy; 2018; 14(5):825-844. PubMed ID: 29634390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD44 promotes Kras-dependent lung adenocarcinoma.
    Zhao P; Damerow MS; Stern P; Liu AH; Sweet-Cordero A; Siziopikou K; Neilson JR; Sharp PA; Cheng C
    Oncogene; 2013 Oct; 32(43):5186-90. PubMed ID: 23208496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylation of the Hippo effector YAP by the methyltransferase SETD7 drives myocardial ischaemic injury: a translational study.
    Ambrosini S; Montecucco F; Kolijn D; Pedicino D; Akhmedov A; Mohammed SA; Herwig M; Gorica E; Szabó PL; Weber L; Russo G; Vinci R; Matter CM; Liuzzo G; Brown PJ; Rossi FMV; Camici GG; Sciarretta S; Beltrami AP; Crea F; Podesser B; Lüscher TF; Kiss A; Ruschitzka F; Hamdani N; Costantino S; Paneni F
    Cardiovasc Res; 2023 Jan; 118(17):3374-3385. PubMed ID: 35709329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysine methylation in cancer: SMYD3-MAP3K2 teaches us new lessons in the Ras-ERK pathway.
    Colón-Bolea P; Crespo P
    Bioessays; 2014 Dec; 36(12):1162-9. PubMed ID: 25382779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PKC
    Garg R; Cooke M; Benavides F; Abba MC; Cicchini M; Feldser DM; Kazanietz MG
    Cancer Res; 2020 Dec; 80(23):5166-5173. PubMed ID: 32994205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer.
    Park J; Cho YH; Shin WJ; Lee SK; Lee J; Kim T; Cha PH; Yang JS; Cho J; Min DS; Han G; Lee HY; Choi KY
    Sci Rep; 2019 Jan; 9(1):648. PubMed ID: 30679620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased Expression of SETD7 Promotes Cell Proliferation by Regulating Cell Cycle and Indicates Poor Prognosis in Hepatocellular Carcinoma.
    Chen Y; Yang S; Hu J; Yu C; He M; Cai Z
    PLoS One; 2016; 11(5):e0154939. PubMed ID: 27183310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.